medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-7-69-74medsovet-1772Research ArticleСердечная недостаточностьHeart failureНОВЫЕ ВОЗМОЖНОСТИ МЕДИКАМЕНТОЗНОГО ЛЕЧЕНИЯ ОСТРОЙ ДЕКОМПЕНСАЦИИ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ ОПЫТ ПРИМЕНЕНИЯ ПРЕПАРАТА СЕРЕЛАКСИН. КЛИНИЧЕСКИЙ СЛУЧАЙNEW PROSPECTS IN PHARMACOLOGICAL TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE. EXPERIENCE WITH SERELAXIN. A CLINICAL CASEМаянскаяС. Д.MayanskayaS. D.

д.м.н., профессор

MD, Prof.

Казанский государственный медицинский университет Минздрава РоссииРоссияKazan State Medical University, Russia’s Ministry of HealthRussian Federation201730122017076974Copyright © Маянская С.Д., 20172017Маянская С.Д.Mayanskaya S.D.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1772

В статье представлены данные о новых возможностях лечения острой сердечной недостаточности с помощью препарата серелаксин, представляющего собой рекомбинантную молекулу, которая идентична нативному пептидному гормону Н2-релаксину человека, а также личный опыт автора по применению данного препарата. Даны сведения о проведенных клинических исследованиях препарата серелаксин. Описан клинический пример длительной 48-часовой внутривенной инфузии серелаксина пациентке с острой декомпенсацией сердечной недостаточности и результаты проведенного лечения. Проведена оценка гемодинамики, профиля безопасности и клинической эффективности у данной больной на фоне лечения серелаксином.

The article tells about new prospects in the treatment of acute heart failure with Serelaxin which is a recombinant molecule identical to the human peptide hormone - H2 relaxin. The author also shares personal experience on the use of the drug. Clinical trials of Serelaxin are reviewed. A clinical case of a prolonged, 48-hour intravenous infusion of Serelaxin to a patient with acute decompensated heart failure and results of the treatment are described. The hemodynamic parameters, safety profile and clinical efficacy in this patient during treatment with Serelaxin are evaluated.

острая декомпенсациясердечная недостаточностьсерелаксинартериальная гипотензияфункция почекacute decompensationcardiac failureserelaxinhypotensionrenal function.ReferencesESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart. J., 2008, 29: 2388-2442.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart. J., 2008, 29: 2388-2442.Murphy NF, Simpson CR, McAlister FA et al. National survey of the prevalence, incidence, primary care burden, and treatment of heart failure in Scotland. Heart, 2004, 90: 1129-1136.Murphy NF, Simpson CR, McAlister FA et al. National survey of the prevalence, incidence, primary care burden, and treatment of heart failure in Scotland. Heart, 2004, 90: 1129-1136.Stewart S, MacIntyre K, Hole DJ. More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur. J. Heart Fail., 2001, 3: 315-322.Stewart S, MacIntyre K, Hole DJ. More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur. J. Heart Fail., 2001, 3: 315-322.Goldsmith L, Weiss G Relaxin in human pregnancy. Ann NY Acad Sci, 2009, 1160: 130-135.Goldsmith L, Weiss G Relaxin in human pregnancy. Ann NY Acad Sci, 2009, 1160: 130-135.5. Bathgate RAD, Hsueh AJW, Sherwood OD Physiology and Molecular Biology of the Relaxin Peptide Family. In: Neill JD (ed). Knobil and Neill’s Physiology of Reproduction, Third Edition. St Louis: Elsevier Publications, 2006: 701-790.5. Bathgate RAD, Hsueh AJW, Sherwood OD Physiology and Molecular Biology of the Relaxin Peptide Family. In: Neill JD (ed). Knobil and Neill’s Physiology of Reproduction, Third Edition. St Louis: Elsevier Publications, 2006: 701-790.6. Bathgate RAD, Halls ML, van der Westhuizen ET et al. Relaxin family receptors and their peptides. Physiol Rev, 2013, 93: 405-480.6. Bathgate RAD, Halls ML, van der Westhuizen ET et al. Relaxin family receptors and their peptides. Physiol Rev, 2013, 93: 405-480.Unemori EN, Lewis M, et al. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen, 2000, 8(5): 361-370.Unemori EN, Lewis M, et al. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen, 2000, 8(5): 361-370.Danielson LA, Sherwood OD et al. Relaxin is a potent renal vasodilator inconscious rats. J Clin Invest, 1999, 103(4): 525-533.Danielson LA, Sherwood OD et al. Relaxin is a potent renal vasodilator inconscious rats. J Clin Invest, 1999, 103(4): 525-533.Teichman SL, E Unemori, JR Teerlink, et al. Relaxin: review of biology and potential role in treating heart failure. Current Heart Failure Reports, 2010, 7: 65-82.Teichman SL, E Unemori, JR Teerlink, et al. Relaxin: review of biology and potential role in treating heart failure. Current Heart Failure Reports, 2010, 7: 65-82.Debrah DO, Conrad KP, et al Effects of relaxin on systemic arterial hemodynamics and mechanical properties in conscious rats: sex dependency and dose response. J Appl Physiol, 2005, 98: 1013–20.Debrah DO, Conrad KP, et al Effects of relaxin on systemic arterial hemodynamics and mechanical properties in conscious rats: sex dependency and dose response. J Appl Physiol, 2005, 98: 1013–20.Teerlink JR, Metra M, Felker GM et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet, 2009, 373(9673): 1429–39.Teerlink JR, Metra M, Felker GM et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet, 2009, 373(9673): 1429–39.Тeerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet, 2013, 381(9860): 29–39.Тeerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet, 2013, 381(9860): 29–39.Metra M, Cotter G, Davison BA et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAXAHF) development program: correlation with outcomes. J Am Coll Cardiol., 2013, 61(2): 196–206.Metra M, Cotter G, Davison BA et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAXAHF) development program: correlation with outcomes. J Am Coll Cardiol., 2013, 61(2): 196–206.Garber SL, Mirochnik Y et al. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int, 2001, 59(3): 876-882.Garber SL, Mirochnik Y et al. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int, 2001, 59(3): 876-882.Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность, 2013, 7(14): 81.Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность, 2013, 7(14): 81.Ушкалова Е.А. Серелаксин: новая надежда на революционный прорыв в лечении острой сердечной недостаточности. Фарматека, 2013, 13: .8-11.Ушкалова Е.А. Серелаксин: новая надежда на революционный прорыв в лечении острой сердечной недостаточности. Фарматека, 2013, 13: .8-11.

The authors declare that there are no conflicts of interest present.